

1477. Prev Med. 2016 Sep;90:52-8. doi: 10.1016/j.ypmed.2016.06.041. Epub 2016 Jun 28.

Risk of second primary cancer after a first potentially-human
papillomavirus-related cancer: A population-based study.

Neumann F(1), Jégu J(2), Mougin C(3), Prétet JL(3), Guizard AV(4), Lapôtre-Ledoux
B(5), Bara S(6), Bouvier V(7), Colonna M(8), Troussard X(9), Trétarre B(10),
Grosclaude P(11), Velten M(2), Woronoff AS(12).

Author information: 
(1)Registre des tumeurs du Doubs et du Territoire de Belfort, University Hospital
Besançon, F-25000 Besançon, France. Electronic address:
florent.neumann@hotmail.fr.
(2)Registre des cancers du Bas-Rhin, Laboratoire d'Épidémiologie et de Santé
Publique, EA3430, FMTS, University of Strasbourg, F-67085 Strasbourg, France;
Service de santé publique, University Hospital of Strasbourg, F-67091 Strasbourg,
France; Francim: Réseau français des registres des cancers, F-31073 Toulouse,
France.
(3)University of Franche-Comte, EA 3181, FED4234, LabExLipSTIC
ANR-11-LABX-0021-FED4234, CIC-1431 F-25000 Besançon, France; University Hospital 
Besançon, F-25000 Besançon, France.
(4)Registre général des tumeurs du Calvados, Cancers & Préventions - U 1086
Inserm, Centre François Baclesse, F-14076, Caen 05, France; Francim: Réseau
français des registres des cancers, F-31073 Toulouse, France.
(5)Registre du cancer de la Somme, Service Épidémiologie Hygiène et Santé
Publique, University Hospital Nord, F-80054 Amiens, France; Francim: Réseau
français des registres des cancers, F-31073 Toulouse, France.
(6)Registre des cancers de la Manche, Hospital of Cotentin, F-50102
Cherbourg-Octeville, France; Francim: Réseau français des registres des cancers, 
F-31073 Toulouse, France.
(7)Registre des tumeurs digestives du Calvados, Cancers & Préventions - U 1086
Inserm, Centre François Baclesse, BP 5026, F-14076, Caen 05, France; Francim:
Réseau français des registres des cancers, F-31073 Toulouse, France.
(8)Registre des cancers de l'Isère, University Hospital Grenoble, BP 217,
F-38043, Grenoble 9, France; Francim: Réseau français des registres des cancers, 
F-31073 Toulouse, France.
(9)Registre des hémopathies malignes de Basse-Normandie, Unité Fonctionnelle
Hospitalo-Universitaire n°0350, University Hospital Caen, F-14033 Caen, France;
Francim: Réseau français des registres des cancers, F-31073 Toulouse, France.
(10)Registre des tumeurs de l'Hérault, Centre de Recherche, F-34298, Montpellier 
5, France; Francim: Réseau français des registres des cancers, F-31073 Toulouse, 
France.
(11)Registre des cancers du Tarn, BP 37, F-81001 Albi, France; Francim: Réseau
français des registres des cancers, F-31073 Toulouse, France.
(12)Registre des tumeurs du Doubs et du Territoire de Belfort, University
Hospital Besançon, F-25000 Besançon, France; University of Franche-Comte, EA
3181, FED4234, LabExLipSTIC ANR-11-LABX-0021-FED4234, CIC-1431 F-25000 Besançon, 
France; Francim: Réseau français des registres des cancers, F-31073 Toulouse,
France.

Human papillomaviruses (HPV) are involved in the development of anogenital and
head and neck cancers. The purpose of this study was to assess the risk of
developing a second primary cancer (SPC) after a first potentially-HPV-related
cancer, and to analyze the sites where SPCs most frequently occurred in these
patients. All patients with a first cancer diagnosed between 1989 and 2004, as
recorded by 10 French cancer registries, were followed up until December 31,
2007. Only invasive potentially-HPV-related cancers (namely, cervical, vagina,
vulva, anal canal, penile, oropharynx, tongue and tonsil) were included.
Standardized Incidence Ratios (SIRs) were calculated to assess the risk of SPC. A
multivariate Poisson regression model was used to model SIRs separately by
gender, adjusted for the characteristics of the first cancer. 10,127 patients
presented a first potentially-HPV-related cancer. The overall SIR was 2.48 (95%
CI, 2.34-2.63). The SIR was 3.59 (95% CI, 3.33-3.86) and 1.61 (95% CI, 1.46-1.78)
in men and women respectively. The relative risk of potentially-HPV-related SPC
was high among these patients (SIR=13.74; 95% CI, 8.80-20.45 and 6.78; 95% CI,
4.61-9.63 for men and women, respectively). Women diagnosed in the most recent
period (2000-2004) showed a 40% increase of their relative risk of SPC as
compared with women diagnosed between 1989 and 1994 (ratio of SIRs=1.40; 95% CI, 
1.06-1.85). HPV cancer survivors face an increased risk of SPC, especially second
cancer. Clinicians may consider this increased risk of developing HPV-related SPC
during follow-up to improve subsequent cancer prevention in these patients.

Copyright © 2016. Published by Elsevier Inc.

DOI: 10.1016/j.ypmed.2016.06.041 
PMID: 27370167  [Indexed for MEDLINE]
